Oral estramustine and oral etoposide for hormone-refractory prostate cancer

Meletios A Dimopoulos; C Panopoulos; Christina Bamia; C. Deliveliotis; G. Alivizatos; D Pantazopoulos; C. Constantinidis; A. Kostakopoulos; Ioannis Kastriotis; Anastasios Zervas; Gerasimos Aravantinos; C Dimopoulos

doi:10.1016/s0090-4295(97)00323-3

Related publications

Article2003

The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group

G.F. Samelis, Dimosthenis Skarlos, Dimitrios Bafaloukos, P. Kosmidis, Αchilles Anagnostopoulos, Gerasimos Aravantinos, Meletios A Dimopoulos

Article2005

The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: A Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group

G.F. Samelis, Haralabos P. Kalofonos, Αδάμος Αδάμου, Paris Kosmides, Dimosthenis Skarlos, Gerasimos Aravantinos, Christos Kiamouris, Oneynadum Adimchi, George Fountzilas, Meletios A Dimopoulos

Article2004

Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer

Raymond P. Abratt, D. Brune, Meletios A Dimopoulos, J. Kliment, J. Breza, Fp Selvaggi, Philippe Beuzeboc, Tomasz Demkow, Stéphane Oudard

Article2008

Biweekly Doxorubicin/Ketoconazole as Second-Line Treatment in Docetaxel-Resistant, Hormone-Refractory Prostate Cancer

G. Lainakis, Nikos Antoniou, G. Alivizatos, Chrisofos Michael, Mitsoyiannis Iraklis, Livadas Konstantinos, Varkarakis Ioannis, Katsifotis Harilaos, Meletios A Dimopoulos, Aristotelis Bamias

Article2000

Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer

Gerasimos Aravantinos, Meletios A Dimopoulos, P Kosmidis, Dimitrios Bafaloukos, Christos Papadimitriou, Christos Kiamouris, N. Pavlidis, K. Sikiotis, Pavlos Papakostas, D. Skarlos